AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...
Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback